The implications of hyperhomocysteinemia in a patient with type 1 diabetes

Acta Clinica Belgica

Volumn 53, Issue 5, 1998, Pages 349-352

  Van Leeuwen Wintjens, H R A J B ^a   Muls, E E ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANGIOGRAPHY; ARTICLE; CASE REPORT; DIET RESTRICTION; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; META ANALYSIS; RISK FACTOR; SCREENING; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE;

ANEMIA, PERNICIOUS; ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 1; GASTRITIS, ATROPHIC; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; RISK FACTORS; VITAMIN B DEFICIENCY;

EID: 0031762763     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Malinow MR. Hyperhornocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation. 1990; 81: 2004-6.
2. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med. 1994; 236: 603-17.
3. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996; 27: 517-27.
4. Rees MM, Rodgers GM. Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis. Thromb Res. 1993; 71: 337-59.
5. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intake. JAMA. 1995; 274: 1049-57.
6. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease, N Engl J Med. 1991; 324: 1149-55.
7. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997; 337: 230-6.
8. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995; 332: 286-91.
9. Den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 1995; 345: 882-5.
10. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997; 277: 1775-81.
11. Colwell JA, Jokl RL. Vascular thrombosis in diabetics. In: Porte D, Sherwin R, Rifkin H, eds. Diabetes Mellitus : Theory and Practice. 5th ed. Norwalk,CT : Appleton and Lange. 1996 : 207-16.
12. Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhornocyst(è)inemia and endothelial dysfunction in IDDM. Diabetes Care. 1997; 20: 1880-6.
13. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus : effect of parenteral methylcobalamin treatment. Atherosclerosis. 1993; 103: 149-57.
14. Munshi MN, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism. 1996; 45: 133-5.
15. Hultberg B, Agardh E, Andersson A, et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest. 1991; 51: 277-82.
16. Agardh C-D, Agardh E, Andersson A, Hultgerg B. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest. 1994; 54: 637-41.
17. Stabler SP, Marcell P, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest. 1988; 81: 466-74.
18. Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. Blood. 1990; 76: 871-8 1.
19. Guttormsen AB, Schneede J, Ueland PM, Refsum H. Kinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency. Am J Clin Nutr. 1996; 63: 194-202.
20. Brattström L. Vitamins as homocysteine-lowering agents. J Nutr. 1996; 126: 1276S-80.
21. Bostom AG, Lathrop L. Hyperhomocysteinemia in endstage renal disease: prevalence, etiology and potential relationship to atherosclerotic outcomes. Kidney Int. 1997; 52: 10-20.
22. Dudman NP, Hicks C, Lynch JF, Wilcken DE, Wabg J. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vivo. Arterioscler Thromb. 1991; 11: 663-70.
23. Rosenberg IH, Bostom A, Jacques P, Selhub J. Genediet interactions in plasma homocysteine regulation. Curr Opin Endocrinol Diabetes. 1996; 3: 497-500.
24. Mancini FP, Di Minno G. Hyperhomocysteinemia and thrombosis: the search for a link. Nutr Metab Cardiovasc Dis. 1996; 6: 168-77.
25. Ungar B, Stocks AE, Martin F, Whittingham S, Mackay IR. Intrinsic-factor antibody, parietal-cell antibody, and latent pernicious anaemia in diabetes mellitus. Lancet. 1968; ii: 415-8.
26. Nerup J, Bendixen G, Binder C. Autoimmunity in diabetes mellitus. Lancet. 1970; ii: 610-1.